BOULDER, Colo., Nov 29, 2010 (BUSINESS WIRE) --
Array BioPharma Inc. (NASDAQ: ARRY) today announced that it will present
data from a Phase 1 trial of KSP inhibitor ARRY-520 in patients with
relapsed/refractory multiple myeloma at the 2010 Annual Meeting of the
American Society of Hematology (ASH) in Orlando, Florida on Saturday,
December 4, 2010.
The abstract can be accessed through the ASH website, www.hematology.org/Meetings/Annual-Meeting.
The abstract title is provided below, however, please note that
according to ASH policy, all data is embargoed until the time of the
beginning of the presentation. The poster will be available as a PDF
after it is presented on Array's website at www.arraybiopharma.com.
|
Event:
|
|
|
2010 Annual Meeting of the American Society of Hematology
|
|
Poster:
|
|
|
A Phase 1/2 Trial of the KSP Inhibitor ARRY-520 in
Relapsed/Refractory Multiple Myeloma (Publication #1959)
|
|
Date:
|
|
|
Saturday, December 4, 2010
|
|
Time:
|
|
|
5:30 - 7:30 p.m. E.T.
|
|
Location:
|
|
|
Orange County Convention Center, Hall A3/A4, Poster Board no.: I-939
|
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small-molecule
drugs to treat patients afflicted with cancer and inflammatory diseases.
Our proprietary drug development pipeline includes clinical candidates
that are designed to regulate therapeutically important target proteins
and are aimed at significant unmet medical needs. For more information
on Array, please go to www.arraybiopharma.com.
SOURCE: Array BioPharma Inc.
Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com
